

Andrew J Vickers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7911304/publications.pdf>

Version: 2024-02-01

600
papers

52,220
citations

1799

103
h-index

2033

205
g-index

621
all docs

621
docs citations

621
times ranked

51285
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimating patient health in prostate cancer treatment counseling. Prostate Cancer and Prostatic Diseases, 2023, 26, 271-275.	3.9	3
2	The Surgical Learning Curve for Biochemical Recurrence After Robot-assisted Radical Prostatectomy. European Urology Oncology, 2023, 6, 414-421.	5.4	13
3	How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?. European Urology Oncology, 2022, 5, 135-137.	5.4	11
4	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	2.5	2
5	Characterization of Symptoms after Radical Prostatectomy and Their Relation to Postoperative Complications. Journal of Urology, 2022, 207, 367-374.	0.4	6
6	Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. European Urology, 2022, 81, 294-304.	1.9	33
7	Association of frailty with 90-day postoperative mortality & geriatric comanagement among older adults with cancer. European Journal of Surgical Oncology, 2022, 48, 903-908.	1.0	8
8	Have urinary function outcomes after radical prostatectomy improved over the past decade?. Cancer, 2022, 128, 1066-1073.	4.1	3
9	Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Iliioinguinal Lymph Node. Journal of Urology, 2022, 207, 1222-1226.	0.4	3
10	Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology. European Urology, 2022, , .	1.9	11
11	Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence. British Journal of Cancer, 2022, 126, 1004-1009.	6.4	2
12	Race, Biology, Disparities, and Prostate Cancer. European Urology, 2022, 81, 463-465.	1.9	2
13	Commentary on Aschmann et al: How do we incorporate harms in analyses of randomized trials?. Clinical Trials, 2022, , 174077452110685.	1.6	0
14	A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative Transrectal Ultrasound Biopsy with Long-Term Followup. Journal of Urology, 2022, 208, 100-108.	0.4	10
15	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. JCO Clinical Cancer Informatics, 2022, 6, e2100154.	2.1	2
16	Do Prediction Models Do More Harm Than Good?. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES122008667.	2.2	3
17	Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. European Journal of Surgical Oncology, 2022, 48, 1427-1432.	1.0	8
18	Decision curve analysis in the evaluation of radiology research. European Radiology, 2022, 32, 5787-5789.	4.5	13

#	ARTICLE	IF	CITATIONS
19	Grade Migration of Prostate Cancer in the United States During the Last Decade. Journal of the National Cancer Institute, 2022, 114, 1012-1019.	6.3	13
20	A qualitative analysis of caregiver burden during the recovery process in ambulatory cancer surgery. Supportive Care in Cancer, 2022, 30, 5713-5721.	2.2	6
21	Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. Journal of Urology, 2022, 208, 309-316.	0.4	7
22	Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance. Journal of Urology, 2022, , 101097JU00000000000002668.	0.4	1
23	Prostate cancer polygenic risk score and prediction of lethal prostate cancer. Npj Precision Oncology, 2022, 6, 25.	5.4	20
24	Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort. European Urology, 2022, 82, 163-169.	1.9	14
25	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD) Tj ETQq1 1 0.784314 rgBT1/Overlook	1.9	0
26	Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041 . European Urology, 2022, 82, e12-e12.	1.9	0
27	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. Journal of Clinical Oncology, 2022, 40, 3110-3114.	1.6	41
28	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000000249103.	0.4	0
29	Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Annals of Surgical Oncology, 2022, , .	1.5	2
30	Systemic immunological determinants of oncological outcomes after surgery for localized renal cell carcinoma. Clinical Genitourinary Cancer, 2022, , .	1.9	0
31	Polygenic risk scores to stratify cancer screening should predict mortality not incidence. Npj Precision Oncology, 2022, 6, .	5.4	5
32	Ureteroâ€œenteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robotâ€œassisted radical cystectomy. BJU International, 2022, 130, 809-814.	2.5	3
33	Prospective validation of microseminoproteinâ€œ2 added to the 4Kscore in predicting highâ€œgrade prostate cancer in an international multicentre cohort. BJU International, 2021, 128, 218-224.	2.5	3
34	Identifying patients with chronic pain who respond to acupuncture: results from an individual patient data meta-analysis. Acupuncture in Medicine, 2021, 39, 83-90.	1.0	7
35	Routine Opioid Prescriptions Are Not Necessary After Breast Excisional Biopsy or Lumpectomy Procedures. Annals of Surgical Oncology, 2021, 28, 303-309.	1.5	8
36	Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duanâ€œs Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304â€œ6. European Urology, 2021, 79, e16.	1.9	0

#	ARTICLE	IF	CITATIONS
37	The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 370-395.	5.4	25
38	Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review. European Urology, 2021, 79, 330-333.	1.9	2
39	Call to increase statistical collaboration in sports science, sport and exercise medicine and sports physiotherapy. British Journal of Sports Medicine, 2021, 55, 118-122.	6.7	26
40	What is a good medical choice?. Cancer, 2021, 127, 1933-1934.	4.1	0
41	Intraoperative Ketorolac is Associated with Risk of Reoperation After Mastectomy: A Single-Center Examination. Annals of Surgical Oncology, 2021, 28, 5134-5140.	1.5	11
42	Patient accrual and understanding of informed consent in a two-stage consent design. Clinical Trials, 2021, 18, 377-382.	1.6	7
43	Higher-Order Musical Temporal Structure in Bird Song. Frontiers in Psychology, 2021, 12, 629456.	2.1	1
44	Decision curve analysis to evaluate the clinical benefit of prediction models. Spine Journal, 2021, 21, 1643-1648.	1.3	109
45	Establishing a global quality of care benchmark report. Health Informatics Journal, 2021, 27, 146045822110157.	2.1	7
46	Applying decision curve analysis to spine surgery. Seminars in Spine Surgery, 2021, 33, 100873.	0.2	1
47	Reply to: "Ketorolac Following Mastectomy: Is There an Increased Risk of Reoperation?" Annals of Surgical Oncology, 2021, 28, 777-778.	1.5	3
48	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. Gynecologic Oncology, 2021, 161, 687-692.	1.4	14
49	Association Between Electronic Patient Symptom Reporting With Alerts and Potentially Avoidable Urgent Care Visits After Ambulatory Cancer Surgery. JAMA Surgery, 2021, 156, 740-746.	4.3	23
50	A Randomized Controlled Trial Evaluating Electronic Outpatient Symptom Monitoring After Ambulatory Cancer Surgery. Annals of Surgery, 2021, 274, 441-448.	4.2	17
51	Active surveillance for prostate cancer. Translational Andrology and Urology, 2021, 10, 2809-2819.	1.4	16
52	Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. European Urology, 2021, 80, 567-572.	1.9	39
53	Clinical utility of subclassifying positive surgical margins at radical prostatectomy. BJU International, 2021, , .	2.5	2
54	Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 979-991.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. <i>European Urology Oncology</i> , 2021, 4, 532-539.	5.4	75
56	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. <i>Urology</i> , 2021, , .	1.0	1
57	Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms. <i>European Urology Open Science</i> , 2021, 30, 13-15.	0.4	2
58	Shared Medical Appointments for Prostate Cancer Active Surveillance Followup Visits. <i>Urology Practice</i> , 2021, 8, 541-545.	0.5	2
59	Reply to Francesco Montorsi, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. <i>Eur Urol</i> 2021;80:567-72. <i>European Urology</i> , 2021, 80, e149.	1.9	0
60	The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial. <i>Journal of Urology</i> , 2021, 206, 662-668.	0.4	6
61	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. <i>Minerva Urology and Nephrology</i> , 2021, 73, 481-488.	2.5	5
62	Sexual and Gender Minority Persons' Perception of the Female Sexual Function Index. <i>Journal of Sexual Medicine</i> , 2021, 18, 2020-2027.	0.6	8
63	From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?. <i>Gut</i> , 2021, , gutjnl-2021-324712.	12.1	1
64	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. <i>European Urology Oncology</i> , 2020, 3, 365-371.	5.4	10
65	Practice Patterns in Reporting Tertiary Grades at Radical Prostatectomy: Survey of a Large Group of Experienced Urologic Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 356-360.	2.5	1
66	Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men. <i>Prostate</i> , 2020, 80, 51-56.	2.3	5
67	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 204-209.	1.6	8
68	Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. <i>European Urology</i> , 2020, 77, 501-507.	1.9	57
69	Risk Factors for Infection after Prostate Biopsy in the United States. <i>Urology</i> , 2020, 138, 113-118.	1.0	11
70	Updating the International Index of Erectile Function: Evaluation of a Large Clinical Data Set. <i>Journal of Sexual Medicine</i> , 2020, 17, 126-132.	0.6	14
71	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. <i>European Urology Oncology</i> , 2020, 3, 474-480.	5.4	15
72	Erectile Function and Sexual Satisfaction: The Importance of Asking About Sexual Desire. <i>Journal of Sexual Medicine</i> , 2020, 17, 349-352.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Screening for Prostate Cancer. Medical Clinics of North America, 2020, 104, 1051-1062.	2.5	79
74	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. Annals of Internal Medicine, 2020, 172, 35.	3.9	203
75	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. Annals of Internal Medicine, 2020, 172, W1.	3.9	83
76	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. Gynecologic Oncology, 2020, 159, 187-194.	1.4	12
77	Reply to Benjamin S. Simpson, Lina M. Carmona Echeverria, Joseph M. Norris, Hashim U. Ahmed, Caroline M. Moore, and Hayley C. Whitaker's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501â€“7. European Urology, 2020, 78, e108-e109.	1.9	0
78	Association of Geriatric Comanagement and 90-Day Postoperative Mortality Among Patients Aged 75 Years and Older With Cancer. JAMA Network Open, 2020, 3, e209265.	5.9	66
79	Do the effects of acupuncture vary between acupuncturists? Analysis of the Acupuncture Trialistsâ€™ Collaboration individual patient data meta-analysis. Acupuncture in Medicine, 2020, 39, 096452842095908.	1.0	6
80	Asian-American Race and Urinary Continence After Radical Prostatectomy. European Urology Open Science, 2020, 22, 51-53.	0.4	3
81	The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1381-1388.	2.5	22
82	Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. European Urology, 2020, 78, 304-306.	1.9	44
83	Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. Urology, 2020, 142, 1-13.	1.0	3
84	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. British Journal of Cancer, 2020, 123, 604-609.	6.4	9
85	Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. BJU International, 2020, 126, 14-25.	2.5	3
86	Systematic review of the use of "magnitude-based inference" in sports science and medicine. PLoS ONE, 2020, 15, e0235318.	2.5	26
87	Statistical Analysis and Reporting Guidelines for CHEST. Chest, 2020, 158, S3-S11.	0.8	9
88	Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodoros van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304â€“6. Prebiopsy MRI: Through the Looking Glass. European Urology, 2020, 78, 314-315.	1.9	3
89	Reply to K.P. Weinfurt et al. Journal of Clinical Oncology, 2020, 38, 653-654.	1.6	0
90	Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer. Journal of the National Cancer Institute, 2020, 112, 1013-1020.	6.3	23

#	ARTICLE	IF	CITATIONS
91	Interfaces for collecting data from patients: 10 golden rules. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 498-500.	4.4	3
92	Three Things About Gleason Grading That Just About Everyone Believes But That Are Almost Certainly Wrong. Urology, 2020, 143, 16-19.	1.0	6
93	Guidelines for Reporting of Figures and Tables for Clinical Research in Urology. European Urology, 2020, 78, 97-109.	1.9	5
94	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127.	0.4	58
95	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121.	0.4	28
96	Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. Journal of Urology, 2020, 204, 281-288.	0.4	19
97	Reply by Authors. Journal of Urology, 2020, 203, 1121-1121.	0.4	0
98	Reply by Authors. Journal of Urology, 2020, 204, 287-288.	0.4	0
99	Biomarker Evaluation and Clinical Development. Soci�t� Internationale D'urologie Journal, 2020, 1, 16-22.	0.4	0
100	Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 672-677.	1.6	11
101	Validation of Patient-Reported Outcomes: A Low Bar. Journal of Clinical Oncology, 2019, 37, 1990-1992.	1.6	8
102	Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools. BMC Medical Research Methodology, 2019, 19, 191.	3.1	7
103	A simple, step-by-step guide to interpreting decision curve analysis. Diagnostic and Prognostic Research, 2019, 3, 18.	1.8	447
104	Impact of intraoperative remifentanyl on postoperative pain and opioid use in thyroid surgery. Journal of Surgical Oncology, 2019, 120, 1456-1461.	1.7	13
105	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
106	Toward Responsible, Informed Decision Making for Prostate Cancer Treatment Decisions. Journal of Clinical Oncology, 2019, 37, 3462-3462.	1.6	2
107	Definitive and sustained increase in prostate cancer metastases in the United States. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 988-990.	1.6	7
108	Magnitude-based Inference is not Bayesian and is not a valid method of inference. Scandinavian Journal of Medicine and Science in Sports, 2019, 29, 1428-1436.	2.9	27

#	ARTICLE	IF	CITATIONS
109	Suitability of outpatient or ambulatory extended recovery cancer surgeries for obese patients. <i>Journal of Clinical Anesthesia</i> , 2019, 58, 111-116.	1.6	7
110	Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e745-e750.	1.9	7
111	Racial Disparities in Low-Risk Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1726.	7.4	4
112	Development and Evaluation of a New Frailty Index for Older Surgical Patients With Cancer. <i>JAMA Network Open</i> , 2019, 2, e193545.	5.9	77
113	Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy. <i>European Urology</i> , 2019, 76, 398-403.	1.9	75
114	A Systematic Review of the Literature Demonstrates Some Errors in the Use of Decision Curve Analysis but Generally Correct Interpretation of Findings. <i>Medical Decision Making</i> , 2019, 39, 493-498.	2.4	17
115	Response to Chappell. <i>Clinical Trials</i> , 2019, 16, 216-216.	1.6	1
116	Ambulatory cancer care electronic symptom self-reporting (ACCESS) for surgical patients: a randomised controlled trial protocol. <i>BMJ Open</i> , 2019, 9, e030863.	1.9	24
117	The Effect of Patient Characteristics on Acupuncture Treatment Outcomes. <i>Clinical Journal of Pain</i> , 2019, 35, 428-434.	1.9	28
118	Introducing BREAST-Q Computerized Adaptive Testing: Short and Individualized Patient-Reported Outcome Assessment following Reconstructive Breast Surgery. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 679-684.	1.4	14
119	Outcomes and Safety Among Patients With Obstructive Sleep Apnea Undergoing Cancer Surgery Procedures in a Freestanding Ambulatory Surgical Facility. <i>Anesthesia and Analgesia</i> , 2019, 129, 360-368.	2.2	21
120	Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. <i>European Urology</i> , 2019, 75, 221-228.	1.9	72
121	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019, 75, 399-407.	1.9	43
122	Development and Validation of Crosswalks for Patient-reported Sexual and Urinary Outcomes Between Commonly Used Instruments. <i>European Urology</i> , 2019, 75, 723-730.	1.9	12
123	Guidelines for Reporting of Statistics for Clinical Research in Urology. <i>European Urology</i> , 2019, 75, 358-367.	1.9	127
124	Comments on "Net reclassification index at event rate: Properties and relationships". <i>Statistics in Medicine</i> , 2019, 38, 497-498.	1.6	1
125	Innovations in Statistical Review at European Urology. <i>European Urology</i> , 2019, 75, 1-2.	1.9	3
126	Joint pain and falls among women with breast cancer on aromatase inhibitors. <i>Supportive Care in Cancer</i> , 2019, 27, 2195-2202.	2.2	8

#	ARTICLE	IF	CITATIONS
127	Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7. European Urology, 2019, 75. e56.	1.9	0
128	Guidelines for reporting of statistics for clinical research in urology. BJU International, 2019, 123, 401-410.	2.5	53
129	Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis. Clinical Chemistry, 2019, 65, 39-41.	3.2	17
130	A Four-kallikrein Panel and β 2-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. European Urology Focus, 2019, 5, 561-567.	3.1	8
131	Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. Journal of Urology, 2019, 201, 77-83.	0.4	30
132	Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer. Journal of Urology, 2019, 201, 535-540.	0.4	19
133	Guidelines for Reporting of Statistics for Clinical Research in Urology. Journal of Urology, 2019, 201, 595-604.	0.4	49
134	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. Journal of Urology, 2019, 202, 108-113.	0.4	67
135	Acupuncture for the prevention of episodic migraine. The Cochrane Library, 2018, 2018, CD001218.	2.8	168
136	Acupuncture for breast cancer-related lymphedema: a randomized controlled trial. Breast Cancer Research and Treatment, 2018, 170, 77-87.	2.5	27
137	Rejoinder. Clinical Trials, 2018, 15, 25-26.	1.6	1
138	Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. European Urology, 2018, 73, 941-948.	1.9	30
139	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. Journal of Urology, 2018, 199, 1470-1474.	0.4	11
140	Re: Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. Journal of Urology, 2018, 199, 1632-1633.	0.4	0
141	Risk Based Surveillance after Surgical Treatment of Renal Cell Carcinoma. Journal of Urology, 2018, 200, 61-67.	0.4	11
142	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	6.4	12
143	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. European Urology, 2018, 73, 890-896.	1.9	87
144	Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration. Ophthalmology, 2018, 125, 391-397.	5.2	36

#	ARTICLE	IF	CITATIONS
145	Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. <i>European Urology</i> , 2018, 73, 961-967.	1.9	14
146	Concordance between patient-reported and physician-reported sexual function after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 80.e1-80.e6.	1.6	3
147	Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?. <i>European Urology</i> , 2018, 73, 33-37.	1.9	11
148	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e113-e120.	1.9	7
149	Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 961-968.	0.4	7
150	Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 947-953.	0.4	47
151	Just-in-time consent: The ethical case for an alternative to traditional informed consent in randomized trials comparing an experimental intervention with usual care. <i>Clinical Trials</i> , 2018, 15, 3-8.	1.6	19
152	Acupuncture for Chronic Pain: Update of an Individual Patient Data Meta-Analysis. <i>Journal of Pain</i> , 2018, 19, 455-474.	1.4	494
153	Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-10.	2.1	5
154	Incorporating Multiple Perspectives Into the Development of an Electronic Survivorship Platform for Head and Neck Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-15.	2.1	13
155	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. <i>Urology</i> , 2018, 122, 121-126.	1.0	5
156	Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening. <i>JAMA Oncology</i> , 2018, 4, 1663.	7.1	27
157	Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. <i>European Urology</i> , 2018, 74, 796-804.	1.9	590
158	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. <i>European Urology</i> , 2018, 74, 465-471.	1.9	189
159	A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. <i>European Urology</i> , 2018, 74, 197-203.	1.9	93
160	Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer. <i>BJU International</i> , 2018, 122, 1003-1009.	2.5	35
161	Prognosis, Effect Modification, and Mediation. <i>European Urology</i> , 2018, 74, 243-245.	1.9	6
162	Reply. <i>Ophthalmology</i> , 2018, 125, e35.	5.2	0

#	ARTICLE	IF	CITATIONS
163	Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort. <i>Journal of Urology</i> , 2018, 200, 1250-1255.	0.4	47
164	A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. <i>European Journal of Cancer</i> , 2018, 101, 12-19.	2.8	72
165	Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139-46. <i>European Urology</i> , 2018, 74, e35-e36.	1.9	2
166	Statistical Code for Clinical Research Papers in a High-Impact Specialist Medical Journal. <i>Annals of Internal Medicine</i> , 2018, 168, 832-833.	3.9	11
167	Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. <i>Urology</i> , 2018, 122, 152-157.	1.0	36
168	Pharmacogenomics of antioxidant supplementation to prevent age-related macular degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5639-E5639.	7.1	2
169	Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups. <i>European Urology</i> , 2018, 74, 535-536.	1.9	11
170	Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. <i>Oncotarget</i> , 2018, 9, 5778-5785.	1.8	1
171	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. <i>ELife</i> , 2018, 7, .	6.0	217
172	Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. <i>European Urology</i> , 2017, 71, 46-52.	1.9	42
173	Implementation of Dynamically Updated Prediction Models at the Point of Care at a Major Cancer Center: Making Nomograms More Like Netflix. <i>Urology</i> , 2017, 102, 1-3.	1.0	9
174	A Systematic Approach to Discussing Active Surveillance with Patients with Low-risk Prostate Cancer. <i>European Urology</i> , 2017, 71, 866-871.	1.9	28
175	Decision Curves, Calibration, and Subgroups. <i>Journal of Clinical Oncology</i> , 2017, 35, 472-473.	1.6	10
176	Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 275-282.	2.5	3
177	Decisional Conflict, Regret, and the Burden of Rational Decision Making. <i>Medical Decision Making</i> , 2017, 37, 3-5.	2.4	29
178	Response to "Comment on: Decisional Conflict, Regret, and the Burden of Rational Decision Making". <i>Medical Decision Making</i> , 2017, 37, E362-E362.	2.4	2
179	Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. <i>Journal of Urology</i> , 2017, 198, 671-677.	0.4	16
180	A systematic review of instrumental variable analyses using geographic region as an instrument. <i>Cancer Epidemiology</i> , 2017, 51, 49-55.	1.9	4

#	ARTICLE	IF	CITATIONS
181	Electronic Rapid Fitness Assessment: A Novel Tool for Preoperative Evaluation of the Geriatric Oncology Patient. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 172-179.	4.9	67
182	Manifesto: towards a clinically-oriented psychometrics. Health and Quality of Life Outcomes, 2017, 15, 83.	2.4	3
183	Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. Journal of Urology, 2017, 197, 1041-1047.	0.4	23
184	Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts. Journal of Urology, 2017, 197, 90-96.	0.4	44
185	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. Journal of Urology, 2017, 197, 607-613.	0.4	18
186	The National Cancer Institute's Conference on Acupuncture for Symptom Management in Oncology: State of the Science, Evidence, and Research Gaps. Journal of the National Cancer Institute Monographs, 2017, 2017, .	2.1	85
187	The Brier score does not evaluate the clinical utility of diagnostic tests or prediction models. Diagnostic and Prognostic Research, 2017, 1, 19.	1.8	66
188	Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. Journal of Clinical Oncology, 2017, 35, 3837-3843.	1.6	42
189	Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS ONE, 2017, 12, e0172749.	2.5	51
190	Acupuncture for chronic pain and depression in primary care: a programme of research. Programme Grants for Applied Research, 2017, 5, 1-316.	1.0	27
191	Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU International, 2016, 117, 740-747.	2.5	28
192	Acupuncture for the prevention of tension-type headache. The Cochrane Library, 2016, 2016, CD007587.	2.8	107
193	NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 509-519.	4.9	268
194	Sharing raw data from clinical trials: what progress since we first asked "Whose data set is it anyway?" Trials, 2016, 17, 227.	1.6	19
195	Incorporating Clinical Considerations into Statistical Analyses of Markers: A Quiet Revolution in How We Think About Data. Clinical Chemistry, 2016, 62, 671-672.	3.2	4
196	An empirical study of race times in recreational endurance runners. BMC Sports Science, Medicine and Rehabilitation, 2016, 8, 26.	1.7	49
197	Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology, 2016, 95, 224.	1.0	0
198	Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain. BMC Medical Research Methodology, 2016, 16, 131.	3.1	11

#	ARTICLE	IF	CITATIONS
199	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. <i>Cancer</i> , 2016, 122, 3386-3393.	4.1	23
200	Beyond prostate-specific antigen. <i>Current Opinion in Urology</i> , 2016, 26, 459-465.	1.8	38
201	Clinical Findings and Treatment Outcomes in Patients with Extraprostatic Extension Identified on Prostate Biopsy. <i>Journal of Urology</i> , 2016, 196, 703-708.	0.4	17
202	Successful external validation of a model to predict other cause mortality in localized prostate cancer. <i>BMC Medicine</i> , 2016, 14, 25.	5.5	22
203	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2705-2711.	1.6	74
204	Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 85-91.	0.6	45
205	The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. <i>Urology</i> , 2016, 91, 12-18.	1.0	54
206	Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. <i>BMJ</i> , The, 2016, 352, i6.	6.0	577
207	A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. <i>European Urology</i> , 2016, 69, 505-511.	1.9	77
208	Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?. <i>Journal of Urology</i> , 2016, 195, 74-79.	0.4	27
209	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. <i>European Urology</i> , 2016, 69, 428-435.	1.9	1,039
210	Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes. <i>European Urology</i> , 2016, 69, 143-148.	1.9	54
211	Prostate Cancer Early Detection, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1534-1561.	4.9	55
212	The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk. <i>Annals of Internal Medicine</i> , 2015, 162, 866-867.	3.9	15
213	Informed Decision Making About Prostate Cancer Screening. <i>Annals of Internal Medicine</i> , 2015, 162, 457-458.	3.9	0
214	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. <i>European Urology Focus</i> , 2015, 1, 75-81.	3.1	6
215	Long-term oncological outcomes of a phase III trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. <i>BJU International</i> , 2015, 116, 50-56.	2.5	16
216	Preoperative predictive model of recovery of urinary continence after radical prostatectomy. <i>BJU International</i> , 2015, 116, 577-583.	2.5	88

#	ARTICLE	IF	CITATIONS
217	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. BJU International, 2015, 116, 366-372.	2.5	4
218	A Systematic Literature Review of Life Expectancy Prediction Tools for Patients with Localized Prostate Cancer. Journal of Urology, 2015, 193, 1938-1942.	0.4	27
219	Lessons of War: Turning Data Into Decisions. EBioMedicine, 2015, 2, 1235-1242.	6.1	29
220	Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2015, 67, 1042-1050.	1.9	453
221	European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. European Urology, 2015, 67, 188-190.	1.9	0
222	Decision Analysis of Dutasteride Use for Patients With Negative Prostate Biopsy. Urology, 2015, 85, 337-342.	1.0	2
223	Reply. Urology, 2015, 85, 342.	1.0	0
224	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	1.9	190
225	Guidelines for Reporting of Statistics in European Urology. European Urology, 2015, 67, 181-187.	1.9	85
226	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. European Urology, 2015, 68, 238-253.	1.9	211
227	Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2015, 67, 1160-1167.	1.9	192
228	Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators. Journal of Biomedical Informatics, 2015, 56, 87-93.	4.3	34
229	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. European Urology, 2015, 68, 139-146.	1.9	156
230	Are we ready to predict late effects? A systematic review of clinically useful prediction models. European Journal of Cancer, 2015, 51, 758-766.	2.8	22
231	The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape. Journal of Urology, 2015, 194, 58-64.	0.4	10
232	Four Flawed Arguments Against Prostate-specific Antigen Screening (and 1 Good One). Urology, 2015, 85, 491-494.	1.0	5
233	Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group. Journal of Clinical Epidemiology, 2015, 68, 426-434.	5.0	15
234	Ambulatory Extended Recovery: Safely Transitioning to Overnight Observation for Minimally Invasive Prostatectomy. Urology Practice, 2015, 2, 121-125.	0.5	4

#	ARTICLE	IF	CITATIONS
235	Spotlight on prostate cancer: the latest evidence and current controversies. BMC Medicine, 2015, 13, 60.	5.5	7
236	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. European Urology, 2015, 68, 1076-1082.	1.9	12
237	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. European Urology, 2015, 68, 756-765.	1.9	57
238	Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era. European Urology Focus, 2015, 1, 149-151.	3.1	0
239	Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Annals of Internal Medicine, 2015, 162, W1-W73.	3.9	3,068
240	Gleason 6 Prostate Cancer: Translating Biology into Population Health. Journal of Urology, 2015, 194, 626-634.	0.4	75
241	Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy. European Urology, 2015, 68, 899-905.	1.9	55
242	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. Journal of the National Cancer Institute, 2015, 107, .	6.3	146
243	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Caseâ€“Control Study. European Urology, 2015, 68, 207-213.	1.9	120
244	Minimally Invasive Partial Nephrectomy Versus Laparoscopic Cryoablation for Patients Newly Diagnosed with a Single Small Renal Mass. European Urology Focus, 2015, 1, 66-72.	3.1	11
245	Calibration of Risk Prediction Models. Medical Decision Making, 2015, 35, 162-169.	2.4	253
246	Response from the author. Clinical Trials, 2014, 11, 628-628.	1.6	0
247	Copy number alteration burden predicts prostate cancer relapse. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11139-11144.	7.1	299
248	Markers for the Early Detection of Prostate Cancer: Some Principles for Statistical Reporting and Interpretation. Journal of Clinical Oncology, 2014, 32, 4033-4034.	1.6	9
249	Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer. Molecular and Cellular Proteomics, 2014, 13, 3082-3096.	3.8	27
250	Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ, The, 2014, 348, g2296-g2296.	6.0	79
251	A Simple Schema for Informed Decision Making About Prostate Cancer Screening. Annals of Internal Medicine, 2014, 161, 441.	3.9	25
252	How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through. Statistics in Medicine, 2014, 33, 3946-3959.	1.6	53

#	ARTICLE	IF	CITATIONS
253	Clinical trials in crisis: Four simple methodologic fixes. <i>Clinical Trials</i> , 2014, 11, 615-621.	1.6	39
254	Characteristics of Acupuncture Treatment Associated with Outcome: Analyses of 17,922 Patients with Chronic Pain in Randomized Controlled Trials. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, A8-A9.	2.1	0
255	Predictors of survival in patients with disease recurrence after radical nephroureterectomy. <i>BJU International</i> , 2014, 113, 911-917.	2.5	28
256	Acupuncture for Chronic Pain. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 955.	7.4	185
257	Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju007-dju007.	6.3	36
258	Urinary Cell mRNA Profiles and Differential Diagnosis of Acute Kidney Graft Dysfunction. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1586-1597.	6.1	45
259	Reply. <i>Urology</i> , 2014, 84, 163.	1.0	0
260	Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening. <i>Journal of Urology</i> , 2014, 192, 724-729.	0.4	37
261	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 433-440.	1.6	31
262	Counseling the Post-radical Prostatectomy Patients About Functional Recovery: High Predictiveness of Current Status. <i>Urology</i> , 2014, 84, 158-163.	1.0	19
263	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. <i>European Urology</i> , 2014, 66, 913-919.	1.9	103
264	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2014, 32, 185-191.	2.2	28
265	Multimorbidity and Evidence Generation. <i>Journal of General Internal Medicine</i> , 2014, 29, 653-660.	2.6	54
266	Increasing value and reducing waste: addressing inaccessible research. <i>Lancet, The</i> , 2014, 383, 257-266.	13.7	692
267	It Ain't What You Do, It's the Way You Do It: Five Golden Rules for Transforming Prostate-Specific Antigen Screening. <i>European Urology</i> , 2014, 66, 188-190.	1.9	21
268	Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. <i>BMC Medicine</i> , 2014, 12, 26.	5.5	88
269	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	1.9	195
270	The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men. <i>European Urology</i> , 2014, 66, 1109-1115.	1.9	74

#	ARTICLE	IF	CITATIONS
271	Can we deliver randomized trials of focal therapy in prostate cancer?. Nature Reviews Clinical Oncology, 2014, 11, 482-491.	27.6	60
272	Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urology, 2014, 14, 25.	1.4	20
273	What Are the Implications of the Surgical Learning Curve?. European Urology, 2014, 65, 532-533.	1.9	13
274	A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer. Urology, 2014, 83, 592-598.	1.0	43
275	Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens. Urology, 2014, 83, 511.e1-511.e7.	1.0	15
276	Effect of Repeated Prostate Biopsies on Erectile Function in Men on Active Surveillance for Prostate Cancer. Journal of Urology, 2014, 191, 744-749.	0.4	47
277	Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low- vs High-grade Prostate Cancer. Urology, 2014, 83, 1362-1368.	1.0	193
278	Does the Net Reclassification Improvement Help Us Evaluate Models and Markers?. Annals of Internal Medicine, 2014, 160, 136-137.	3.9	45
279	Prostate Cancer Early Detection, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1211-1219.	4.9	76
280	Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 768-771.	4.9	8
281	Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. The Cochrane Library, 2014, , CD002285.	2.8	5
282	Influence of Control Group on Effect Size in Trials of Acupuncture for Chronic Pain: A Secondary Analysis of an Individual Patient Data Meta-Analysis. PLoS ONE, 2014, 9, e93739.	2.5	94
283	Who should be included in a clinical trial of screening for bladder cancer?. Cancer, 2013, 119, 143-149.	4.1	35
284	Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Supportive Care in Cancer, 2013, 21, 1735-1741.	2.2	56
285	Writing Up Clinical Research: A Statistician's View. Journal of General Internal Medicine, 2013, 28, 1127-1129.	2.6	5
286	Treating Metastatic Disease: Which Survival Model Is Best Suited for the Clinic?. Clinical Orthopaedics and Related Research, 2013, 471, 843-850.	1.5	38
287	Four-hundredfold overestimation of biopsy mortality. BJU International, 2013, 111, E16-7.	2.5	1
288	Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam. European Urology, 2013, 64, 693-699.	1.9	78

#	ARTICLE	IF	CITATIONS
289	A Phase II, Randomized, Controlled Trial of Acupuncture for Reduction of Postcolectomy Ileus. <i>Annals of Surgical Oncology</i> , 2013, 20, 1164-1169.	1.5	31
290	Re: Comparative Effectiveness of Alternative Prostate-specific Antigen-Based Prostate Cancer Screening Strategies: Model Estimates of Potential Benefits and Harms. <i>European Urology</i> , 2013, 64, 682-683.	1.9	1
291	Re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. <i>Eur Urol</i> 2012;62:472-487. <i>European Urology</i> , 2013, 63, e50.	1.9	3
292	Prostate-specific Antigen Velocity: New Methods, Same Results, Still No Evidence of Clinical Utility. <i>European Urology</i> , 2013, 64, 394-396.	1.9	6
293	A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. <i>European Urology</i> , 2013, 64, 786-798.	1.9	172
294	Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial. <i>European Urology</i> , 2013, 64, 873-875.	1.9	43
295	A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. <i>BJU International</i> , 2013, 111, 206-212.	2.5	41
296	Why is PSA velocity such a sticky concept?. <i>Nature Reviews Urology</i> , 2013, 10, 189-190.	3.8	4
297	Timing of Curative Treatment for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2013, 64, 204-215.	1.9	112
298	A simple decision analytic solution to the comparison of two binary diagnostic tests. <i>Statistics in Medicine</i> , 2013, 32, 1865-1876.	1.6	13
299	Statistics Notes: Missing outcomes in randomised trials. <i>BMJ, The</i> , 2013, 346, f3438-f3438.	6.0	37
300	Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. <i>BMJ, The</i> , 2013, 346, f2023-f2023.	6.0	221
301	Responses to the Acupuncture Trialists' Collaboration Individual Patient Data Meta-Analysis. <i>Acupuncture in Medicine</i> , 2013, 31, 98-100.	1.0	4
302	Evaluation of Prediction Models for Decision-Making: Beyond Calibration and Discrimination. <i>PLoS Medicine</i> , 2013, 10, e1001491.	8.4	43
303	Placing Acupuncture in PerspectiveReply. <i>JAMA Internal Medicine</i> , 2013, 173, 713.	5.1	0
304	Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. <i>Journal of the National Cancer Institute</i> , 2013, 105, 237-243.	6.3	42
305	The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. <i>Cancer</i> , 2013, 119, 3007-3011.	4.1	15
306	Acupuncture in the treatment of upper-limb lymphedema. <i>Cancer</i> , 2013, 119, 2455-2461.	4.1	64

#	ARTICLE	IF	CITATIONS
307	Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. <i>International Journal of Cancer</i> , 2013, 133, 1452-1458.	5.1	64
308	Anti-GD2 antibody 3F8 and barley-derived (1 → 3), (1 → 4)-β-D-glucan. <i>Oncolmunology</i> , 2013, 2, e234024.	4.6	30
309	Evaluation of Markers and Risk Prediction Models. <i>Medical Decision Making</i> , 2013, 33, 490-501.	2.4	71
310	Can one blood draw replace transrectal ultrasonographyâ€estimated prostate volume to predict prostate cancer risk?. <i>BJU International</i> , 2013, 112, 602-609.	2.5	10
311	If something looks too good to be true, it probably is. <i>BJU International</i> , 2013, 112, 430-431.	2.5	1
312	Counterpoint: Prostate-Specific Antigen Velocity Is Not of Value for Early Detection of Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 286-290.	4.9	6
313	Characteristics of Acupuncture Treatment Associated with Outcome: An Individual Patient Meta-Analysis of 17,922 Patients with Chronic Pain in Randomised Controlled Trials. <i>PLoS ONE</i> , 2013, 8, e77438.	2.5	101
314	Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review. <i>Journal of Clinical Oncology</i> , 2012, 30, 2581-2584.	1.6	114
315	Pilot Randomized Controlled Trial of Individual Meaning-Centered Psychotherapy for Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1304-1309.	1.6	316
316	Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion. <i>Journal of Oncology Practice</i> , 2012, 8, 315-317.	2.5	9
317	Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1993-1998.	2.3	8
318	Screening for Prostate Cancer. <i>Annals of Internal Medicine</i> , 2012, 156, 539.	3.9	1
319	Acupuncture for Chronic Pain. <i>Archives of Internal Medicine</i> , 2012, 172, 1444.	3.8	835
320	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012, 30, 181-187.	2.2	66
321	Comparison of Three Different Tools for Prediction of Seminal Vesicle Invasion at Radical Prostatectomy. <i>European Urology</i> , 2012, 62, 590-596.	1.9	12
322	Reply to Michael Froehner and Manfred P. Wirth's Letter to the Editor re: Andrew Vickers, Caroline Bennette, Gunnar Steineck, et al. Individualized Estimation of the Benefit of Radical Prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial. <i>Eur Urol</i> 2012;62:204â€“9. <i>European Urology</i> , 2012, 62, e54.	1.9	0
323	Editorial Comment. <i>Journal of Urology</i> , 2012, 187, 1638-1638.	0.4	0
324	PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. <i>British Journal of Medical and Surgical Urology</i> , 2012, 5, 162-168.	0.2	82

#	ARTICLE	IF	CITATIONS
325	Pelvic Lymph Node Dissection for Patients with Elevated Risk of Lymph Node Invasion During Radical Prostatectomy: Comparison of Open, Laparoscopic and Robot-Assisted Procedures. Journal of Endourology, 2012, 26, 748-753.	2.1	48
326	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. Annals of Surgical Oncology, 2012, 19, 4337-4344.	1.5	53
327	We Need a Better Marker for Prostate Cancer. How About Renaming PSA?. Urology, 2012, 79, 254-255.	1.0	10
328	Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of Clinical Oncology, 2012, 30, 3020-3025.	1.6	128
329	Time for another rethink on prostate cancer screening. Nature Reviews Clinical Oncology, 2012, 9, 7-8.	27.6	1
330	Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Medical Research Methodology, 2012, 12, 21.	3.1	285
331	Screening for Prostate Cancer: Early Detection or Overdetection?. Annual Review of Medicine, 2012, 63, 161-170.	12.2	43
332	Predicting prostate cancer many years before diagnosis: how and why?. World Journal of Urology, 2012, 30, 131-135.	2.2	17
333	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World Journal of Urology, 2012, 30, 149-155.	2.2	101
334	Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU International, 2012, 109, 1-7.	2.5	17
335	Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. European Journal of Clinical Investigation, 2012, 42, 216-228.	3.4	165
336	How Do You Know If You Are Any Good? A Surgeon Performance Feedback System for the Outcomes of Radical Prostatectomy. European Urology, 2012, 61, 284-289.	1.9	28
337	Evaluation of Multiple Risk-Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men. European Urology, 2012, 61, 471-477.	1.9	46
338	Risk-Based Prostate Cancer Screening. European Urology, 2012, 61, 652-661.	1.9	102
339	PSA is Dead, Long Live PSA. European Urology, 2012, 61, 467-468.	1.9	8
340	Individualized Estimation of the Benefit of Radical Prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial. European Urology, 2012, 62, 204-209.	1.9	99
341	Re: Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results After 13 Years of Follow-up. European Urology, 2012, 62, 353.	1.9	0
342	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion, 2012, 52, 1363-1378.	1.6	11

#	ARTICLE	IF	CITATIONS
343	The trifecta: great concept, lousy statistic. BJU International, 2012, 110, 771-772.	2.5	4
344	Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy. Trials, 2012, 13, 23.	1.6	6
345	A Personalized Automated Messaging System to Improve Adherence to Prostate Cancer Screening: Research Protocol. JMIR Research Protocols, 2012, 1, e20.	1.0	8
346	Statistical Considerations for Patient Selection and Triggers for Intervention in Active Surveillance. , 2012, , 121-129.		0
347	Incidence-based analysis of lethal prostate cancer in Swedish counties with high versus low incidence of prostate cancer in nationwide, population-based registries.. Journal of Clinical Oncology, 2012, 30, 4668-4668.	1.6	0
348	Role of Prostate Specific Antigen and Immediate Confirmatory Biopsy in Predicting Progression During Active Surveillance for Low Risk Prostate Cancer. Journal of Urology, 2011, 185, 477-482.	0.4	165
349	Tumor markers in prostate cancer I: Blood-based markers. Acta OncolÃ³gica, 2011, 50, 61-75.	1.8	144
350	A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td	4.1	50
351	Great Meaningless Questions in Urology: Which Is Better, Open, Laparoscopic, or Robotic Radical Prostatectomy?. Urology, 2011, 77, 1025-1026.	1.0	11
352	Editorial Comment. Urology, 2011, 78, 606.	1.0	0
353	Editorial Comment. Urology, 2011, 78, 1368.	1.0	1
354	What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public?. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 118-123.	1.6	2
355	Intraâ€œindividual shortâ€œterm variability of prostateâ€œspecific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. BJU International, 2011, 107, 1769-1774.	2.5	10
356	Prediction models in cancer care. Ca-A Cancer Journal for Clinicians, 2011, 61, 315-326.	329.8	75
357	Cancer Control and Functional Outcomes After Radical Prostatectomy as Markers of Surgical Quality: Analysis of Heterogeneity Between Surgeons at a Single Cancer Center. European Urology, 2011, 59, 317-322.	1.9	105
358	Extent of Pelvic Lymph Node Dissection and the Impact of Standard Template Dissection on Nomogram Prediction of Lymph Node Involvement. European Urology, 2011, 60, 195-201.	1.9	90
359	Re: Population-Based Patterns and Predictors of Prostate-Specific Antigen Screening Among Older Men in the United States. European Urology, 2011, 60, 392.	1.9	0
360	The Surgical Learning Curve for Artificial Urinary Sphincter Procedures Compared to Typical Surgeon Experience. European Urology, 2011, 60, 1285-1290.	1.9	61

#	ARTICLE	IF	CITATIONS
361	One statistical test is sufficient for assessing new predictive markers. BMC Medical Research Methodology, 2011, 11, 13.	3.1	149
362	Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer, 2011, 117, 1210-1219.	4.1	121
363	Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 2011, 117, 2577-2578.	4.1	2
364	Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology. Cancer, 2011, 117, 2892-2897.	4.1	51
365	Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 2011, 117, 3532-3533.	4.1	1
366	Reverse stage shift at a tertiary care center. Cancer, 2011, 117, 4855-4860.	4.1	62
367	Surgery confounds biology: The predictive value of stage, grade and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience. International Journal of Cancer, 2011, 128, 1697-1702.	5.1	6
368	Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. International Journal of Cancer, 2011, 128, 2373-2381.	5.1	18
369	Prediction Models: Revolutionary in Principle, But Do They Do More Good Than Harm?. Journal of Clinical Oncology, 2011, 29, 2951-2952.	1.6	63
370	A Safety and Efficacy Pilot Study of Acupuncture for the Treatment of Chronic Lymphoedema. Acupuncture in Medicine, 2011, 29, 170-172.	1.0	38
371	Making raw data more widely available. BMJ: British Medical Journal, 2011, 342, d2323-d2323.	2.3	26
372	Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection. Journal of the National Cancer Institute, 2011, 103, 1635-1636.	6.3	4
373	A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 255-261.	2.5	84
374	An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection. Journal of the National Cancer Institute, 2011, 103, 462-469.	6.3	113
375	Re: Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data. Journal of the National Cancer Institute, 2011, 103, 1134-1134.	6.3	5
376	Do the Data Support the Comorbidity Hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Results?. Journal of Clinical Oncology, 2011, 29, e387-e387.	1.6	10
377	Assessing the Learning Curve for Prostate Cancer Surgery. , 2011, , 49-60.		2
378	Author's Response: Probabilistic Predictions, Medical Decisions, and Clinical Usefulness. Epidemiology, 2010, 21, 142-143.	2.7	0

#	ARTICLE	IF	CITATIONS
379	Fellowship Training as a Modifier of the Surgical Learning Curve. <i>Academic Medicine</i> , 2010, 85, 863-868.	1.6	33
380	Traditional Statistical Methods for Evaluating Prediction Models Are Uninformative as to Clinical Value: Towards a Decision Analytic Framework. <i>Seminars in Oncology</i> , 2010, 37, 31-38.	2.2	93
381	Sixty Years of CA: A Cancer Journal for Clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 345-350.	329.8	97
382	A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. <i>BMC Cancer</i> , 2010, 10, 635.	2.6	70
383	Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. <i>BMC Medical Informatics and Decision Making</i> , 2010, 10, 34.	3.0	32
384	A regret theory approach to decision curve analysis: A novel method for eliciting decision makers' preferences and decision-making. <i>BMC Medical Informatics and Decision Making</i> , 2010, 10, 51.	3.0	70
385	Validation study of a web-based assessment of functional recovery after radical prostatectomy. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 82.	2.4	59
386	Data and programming code from the studies on the learning curve for radical prostatectomy. <i>BMC Research Notes</i> , 2010, 3, 234.	1.4	5
387	Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. <i>European Urology</i> , 2010, 58, 687-700.	1.9	132
388	Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen. <i>Cancer</i> , 2010, 116, 2612-2620.	4.1	61
389	Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. <i>Cancer</i> , 2010, 116, 5226-5234.	4.1	286
390	Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. <i>Trials</i> , 2010, 11, 9.	1.6	70
391	Individual patient data meta-analysis of acupuncture for chronic pain: protocol of the Acupuncture Trialists' Collaboration. <i>Trials</i> , 2010, 11, 90.	1.6	55
392	Reply to D.A. Hamstra et al and A.P. Sandhu. <i>Journal of Clinical Oncology</i> , 2010, 28, e521-e522.	1.6	0
393	Assessing the Performance of Prediction Models. <i>Epidemiology</i> , 2010, 21, 128-138.	2.7	3,387
394	Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 611-619.	1.5	60
395	Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication. <i>Journal of Clinical Oncology</i> , 2010, 28, 2493-2498.	1.6	204
396	Finasteride to Prevent Prostate Cancer: Should All Men or Only a High-Risk Subgroup Be Treated?. <i>Journal of Clinical Oncology</i> , 2010, 28, 1112-1116.	1.6	19

#	ARTICLE	IF	CITATIONS
397	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010, 16, 4374-4381.	7.0	86
398	A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. <i>Clinical Cancer Research</i> , 2010, 16, 3232-3239.	7.0	106
399	Dutasteride reduces incident prostate cancer in men after negative prostate biopsy. <i>Evidence-Based Medicine</i> , 2010, 15, 119-120.	0.6	1
400	Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1201-1207.	2.5	30
401	Acupuncture for Pain and Dysfunction After Neck Dissection: Results of a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2565-2570.	1.6	155
402	Reducing Systematic Review to a Cut and Paste. <i>Research in Complementary Medicine</i> , 2010, 17, 303-305.	2.2	4
403	Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. <i>BMJ: British Medical Journal</i> , 2010, 340, c181-c181.	2.3	126
404	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. <i>BMJ: British Medical Journal</i> , 2010, 341, c4521-c4521.	2.3	195
405	Susceptibility Loci Associated with Prostate Cancer Progression and Mortality. <i>Clinical Cancer Research</i> , 2010, 16, 2819-2832.	7.0	74
406	The Learning Curve for Surgical Margins After Open Radical Prostatectomy: Implications for Margin Status as an Oncological End Point. <i>Journal of Urology</i> , 2010, 183, 1360-1365.	0.4	86
407	Definition of Biochemical Recurrence After Radical Prostatectomy Does Not Substantially Impact Prognostic Factor Estimates. <i>Journal of Urology</i> , 2010, 183, 984-989.	0.4	36
408	Complications After Radical and Partial Nephrectomy as a Function of Age. <i>Journal of Urology</i> , 2010, 183, 1725-1730.	0.4	72
409	How Do You Tell Whether a Change in Surgical Technique Leads to a Change in Outcome?. <i>Journal of Urology</i> , 2010, 183, 1510-1514.	0.4	13
410	Variations Among Experienced Surgeons in Cancer Control After Open Radical Prostatectomy. <i>Journal of Urology</i> , 2010, 183, 977-983.	0.4	61
411	1986 AN EMPIRICAL EVALUATION OF THE NATIONAL CANCER CENTER NETWORK GUIDELINES ON PROSTATE SPECIFIC ANTIGEN VELOCITY IN PROSTATE CANCER DETECTION. <i>Journal of Urology</i> , 2010, 183, .	0.4	2
412	596 CANCER CONTROL DOES NOT REQUIRE SACRIFICE OF FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY: ANALYSIS OF HETEROGENEITY BETWEEN SURGEONS AT A SINGLE CANCER CENTER. <i>Journal of Urology</i> , 2010, 183, .	0.4	1
413	Why Can't Nomograms Be More Like Netflix?. <i>Urology</i> , 2010, 75, 511-513.	1.0	12
414	Everything You Always Wanted to Know About Evaluating Prediction Models (But Were Too Afraid to) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	84

#	ARTICLE	IF	CITATIONS
415	Statistical consideration for clinical biomarker research in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 389-400.	1.6	119
416	The Learning Curve for Laparoscopic Radical Prostatectomy: An International Multicenter Study. Journal of Urology, 2010, 184, 2291-2296.	0.4	125
417	Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy. Journal of Urology, 2010, 184, 907-912.	0.4	24
418	Metastasis After Radical Prostatectomy or External Beam Radiotherapy for Patients With Clinically Localized Prostate Cancer: A Comparison of Clinical Cohorts Adjusted for Case Mix. Journal of Clinical Oncology, 2010, 28, 1508-1513.	1.6	286
419	Pretreatment Prostate-Specific Antigen (PSA) Velocity and Doubling Time Are Associated With Outcome but Neither Improves Prediction of Outcome Beyond Pretreatment PSA Alone in Patients Treated With Radical Prostatectomy. Journal of Clinical Oncology, 2009, 27, 3591-3597.	1.6	79
420	Prostate Cancerâ€“Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. Journal of Clinical Oncology, 2009, 27, 4300-4305.	1.6	417
421	Cutpoints in Clinical Chemistry: Time for Fundamental Reassessment. Clinical Chemistry, 2009, 55, 15-17.	3.2	27
422	Long-Term Health Outcomes of a Decision Aid: Data from a Randomized Trial of Adjuvant! in Women with Localized Breast Cancer. Medical Decision Making, 2009, 29, 461-467.	2.4	9
423	Estimating the benefits of PSA screening. Nature Reviews Urology, 2009, 6, 301-303.	3.8	17
424	The Acupuncture Trialistsâ€” Collaboration: Individual Patient Data Meta-Analysis of Chronic Pain Trials. Acupuncture in Medicine, 2009, 27, 126-127.	1.0	7
425	Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 398-403.	1.6	225
426	Oncologic Outcome after Laparoscopic Radical Prostatectomy: 10 Years of Experience. European Urology, 2009, 55, 1014-1019.	1.9	63
427	Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort. European Urology, 2009, 56, 753-760.	1.9	65
428	Evaluation of molecular forms of prostateâ€“specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. International Journal of Cancer, 2009, 124, 659-663.	5.1	20
429	Comparison of models to predict clinical failure after radical prostatectomy. Cancer, 2009, 115, 303-310.	4.1	17
430	Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer, 2009, 115, 1005-1010.	4.1	71
431	Clinical benefits of a multivariate prediction model for bladder cancer. Cancer, 2009, 115, 5460-5469.	4.1	32
432	A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1215-1221.	2.5	167

#	ARTICLE	IF	CITATIONS
433	Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology, 2009, 65, 67-71.	2.3	55
434	Net reclassification improvement and decision theory. Statistics in Medicine, 2009, 28, 525-526.	1.6	22
435	The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost. Trials, 2009, 10, 14.	1.6	68
436	Using Relative Utility Curves to Evaluate Risk Prediction. Journal of the Royal Statistical Society Series A: Statistics in Society, 2009, 172, 729-748.	1.1	120
437	THE CONTINUING ROLE OF PROSTATE-SPECIFIC ANTIGEN AS A MARKER FOR LOCALIZED PROSTATE CANCER: "DO NOT THROW THE BABY OUT WITH THE BATH WATER". BJU International, 2009, 104, 1553-1554.	2.5	4
438	Comparison of Observed Biochemical Recurrence-free Survival in Patients With Low PSA Values Undergoing Radical Prostatectomy and Predictions of Preoperative Nomogram. Urology, 2009, 73, 1098-1103.	1.0	15
439	Acupuncture for tension-type headache. , 2009, , CD007587.		190
440	Critical review of prostate cancer predictive tools. Future Oncology, 2009, 5, 1555-1584.	2.4	162
441	The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncology, The, 2009, 10, 475-480.	10.7	247
442	Is it Necessary to Remove the Seminal Vesicles Completely at Radical Prostatectomy? Decision Curve Analysis of European Society of Urologic Oncology Criteria. Journal of Urology, 2009, 181, 609-614.	0.4	22
443	Contemporary Use of Partial Nephrectomy at a Tertiary Care Center in the United States. Journal of Urology, 2009, 181, 993-997.	0.4	147
444	Low Annual Caseloads of United States Surgeons Conducting Radical Prostatectomy. Journal of Urology, 2009, 182, 2677-2681.	0.4	65
445	Acupuncture for migraine prophylaxis. , 2009, , CD001218.		272
446	Homoeopathic Oscillococtinum for preventing and treating influenza and influenza-like syndromes. , 2009, , CD001957.		7
447	Empirical Study of Data Sharing by Authors Publishing in PLoS Journals. PLoS ONE, 2009, 4, e7078.	2.5	282
448	Phase II designs for anticancer botanicals and supplements. Society for Integrative Oncology, 2009, 7, 35-40.	0.7	1
449	New Prognostic Markers: The Pathway from Research to Clinical Practice. , 2009, 8, 7-13.		0
450	Do we want more cancer patients on clinical trials If so, what are the barriers to greater accrual. Trials, 2008, 9, 31.	1.6	12

#	ARTICLE	IF	CITATIONS
451	Systematic review of statistical methods used in molecular marker studies in cancer. <i>Cancer</i> , 2008, 112, 1862-1868.	4.1	35
452	Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. <i>Cancer</i> , 2008, 112, 2384-2392.	4.1	281
453	Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. <i>Nature Reviews Cancer</i> , 2008, 8, 268-278.	28.4	713
454	Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function. <i>BJU International</i> , 2008, 101, 1217-1222.	2.5	65
455	Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: a simulation study. <i>BMC Medical Research Methodology</i> , 2008, 8, 75.	3.1	35
456	Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. <i>BMC Medical Informatics and Decision Making</i> , 2008, 8, 53.	3.0	966
457	A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Gästeborg, Sweden. <i>BMC Medicine</i> , 2008, 6, 19.	5.5	212
458	Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. <i>BMC Medicine</i> , 2008, 6, 6.	5.5	95
459	Multi-institutional Study of Symptomatic Deep Venous Thrombosis and Pulmonary Embolism in Prostate Cancer Patients Undergoing Laparoscopic or Robot-Assisted Laparoscopic Radical Prostatectomy. <i>European Urology</i> , 2008, 53, 134-145.	1.9	127
460	Effects of Pathologic Stage on the Learning Curve for Radical Prostatectomy: Evidence That Recurrence in Organ-Confined Cancer Is Largely Related to Inadequate Surgical Technique. <i>European Urology</i> , 2008, 53, 960-966.	1.9	100
461	Editorial Comment on: Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. <i>European Urology</i> , 2008, 54, 802-803.	1.9	5
462	Randomized controlled trial of a special acupuncture technique for pain after thoracotomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1464-1469.	0.8	55
463	Longitudinal Risk of Upper Tract Recurrence Following Radical Cystectomy for Urothelial Cancer and the Potential Implications for Long-Term Surveillance. <i>Journal of Urology</i> , 2008, 179, 96-100.	0.4	73
464	What do we mean by "outcome can be predicted"? <i>American Heart Journal</i> , 2008, 156, e11.	2.7	2
465	Evaluation of widely consumed botanicals as immunological adjuvants. <i>Vaccine</i> , 2008, 26, 4860-4865.	3.8	55
466	Surgeon Experience is Strongly Associated With Biochemical Recurrence After Radical Prostatectomy for All Preoperative Risk Categories. <i>Journal of Urology</i> , 2008, 179, 2212-2217.	0.4	129
467	Comprehensive Prospective Comparative Analysis of Outcomes Between Open and Laparoscopic Radical Prostatectomy Conducted in 2003 to 2005. <i>Journal of Urology</i> , 2008, 179, 1811-1817.	0.4	147
468	Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular Markers. <i>American Statistician</i> , 2008, 62, 314-320.	1.6	122

#	ARTICLE	IF	CITATIONS
469	Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?. Journal of the National Cancer Institute, 2008, 100, 773-783.	6.3	406
470	Decision Curve Analysis: A Discussion. Medical Decision Making, 2008, 28, 146-149.	2.4	109
471	Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population. Journal of Clinical Oncology, 2008, 26, 835-841.	1.6	95
472	Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer. Cancer Research, 2008, 68, 2132-2144.	0.9	114
473	The Status and Future of Acupuncture Clinical Research. Journal of Alternative and Complementary Medicine, 2008, 14, 871-881.	2.1	70
474	Against Diagnosis. Annals of Internal Medicine, 2008, 149, 200.	3.9	58
475	Basic introduction to research: how not to do research. Society for Integrative Oncology, 2008, 6, 82-5.	0.7	3
476	Living proof and the pseudoscience of alternative cancer treatments. Society for Integrative Oncology, 2008, 6, 37-40.	0.7	2
477	Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer. Clinical Chemistry, 2007, 53, 233-240.	3.2	57
478	Setting the Bar in Phase II Trials: The Use of Historical Data for Determining "Go/No Go" Decision for Definitive Phase III Testing. Clinical Cancer Research, 2007, 13, 972-976.	7.0	66
479	Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients. Journal of Clinical Oncology, 2007, 25, 5584-5590.	1.6	171
480	Measurements of Proteases or Protease System Components in Blood to Enhance Prediction of Disease Risk or Outcome in Possible Cancer. Journal of Clinical Oncology, 2007, 25, 347-348.	1.6	10
481	How should we define patients who are at high risk of death from prostate cancer?. Nature Reviews Urology, 2007, 4, 646-647.	1.4	0
482	Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 2007, 25, 5603-5608.	1.6	92
483	The Surgical Learning Curve for Prostate Cancer Control After Radical Prostatectomy. Journal of the National Cancer Institute, 2007, 99, 1171-1177.	6.3	368
484	Complementary Therapies and Integrative Oncology in Lung Cancer. Chest, 2007, 132, 340S-354S.	0.8	86
485	Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence. Journal of the National Cancer Institute, 2007, 99, 1484-1489.	6.3	198
486	Association of Cysteine-Rich Secretory Protein 3 and β 2-Microseminoprotein with Outcome after Radical Prostatectomy. Clinical Cancer Research, 2007, 13, 4130-4138.	7.0	76

#	ARTICLE	IF	CITATIONS
487	Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years. <i>Journal of Clinical Oncology</i> , 2007, 25, 431-436.	1.6	187
488	Radical Prostatectomy Shortly After Prostate Biopsy Does Not Affect Operative Difficulty or Efficacy. <i>Urology</i> , 2007, 69, 1128-1133.	1.0	27
489	Prognostic Significance of Location of Positive Margins in Radical Prostatectomy Specimens. <i>Urology</i> , 2007, 70, 965-969.	1.0	182
490	Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. <i>Journal of Urology</i> , 2007, 177, 1283-1286.	0.4	146
491	Cyclin D1, a Novel Molecular Marker of Minimal Residual Disease, in Metastatic Neuroblastoma. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 237-241.	2.8	21
492	Hyperthermie â€“ Symposium aus Anlass des 80. Jahrestages der Verleihung des Nobelpreises fÃ¼r Medizin an Julius Wagner-Jauregg. <i>Complementary Medicine Research</i> , 2007, 14, 365-370.	1.2	0
493	Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. <i>International Journal of Cancer</i> , 2007, 120, 1499-1504.	5.1	41
494	The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologicallyâ€based screening strategy. <i>International Journal of Cancer</i> , 2007, 121, 2212-2217.	5.1	42
495	Method for evaluating prediction models that apply the results of randomized trials to individual patients. <i>Trials</i> , 2007, 8, 14.	1.6	81
496	Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. <i>International Journal of Urology</i> , 2007, 14, 26-32.	1.0	57
497	Preoperative and Intraoperative Risk Factors for Side-Specific Positive Surgical Margins in Laparoscopic Radical Prostatectomy for Prostate Cancer. <i>European Urology</i> , 2007, 51, 764-771.	1.9	71
498	Risk-Adjusted Analysis of Positive Surgical Margins Following Laparoscopic and Retropubic Radical Prostatectomy. <i>European Urology</i> , 2007, 52, 1090-1096.	1.9	39
499	Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial. <i>Journal of Headache and Pain</i> , 2007, 8, 306-314.	6.0	110
500	How to Improve Accrual to Clinical Trials of Symptom Control 1: Recruitment Strategies. <i>Society for Integrative Oncology</i> , 2007, 05, 38.	0.7	6
501	How to Improve Accrual to Clinical Trials of Symptom Control 2: Design Issues. <i>Society for Integrative Oncology</i> , 2007, 05, 61.	0.7	8
502	Which Botanicals or Other Unconventional Anticancer Agents Should We Take to Clinical Trial?. <i>Society for Integrative Oncology</i> , 2007, 05, 125.	0.7	14
503	Association Between Urinary Cytology and Pathology for Nontransitional Cell Malignancies of the Urinary Tract. <i>Journal of Urology</i> , 2006, 175, 2038-2041.	0.4	10
504	Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2006, 7, 735-740.	10.7	1,456

#	ARTICLE	IF	CITATIONS
505	Poorly Differentiated Prostate Cancer Treated With Radical Prostatectomy: Long-Term Outcome and Incidence of Pathological Downgrading. Journal of Urology, 2006, 176, 991-995.	0.4	137
506	Primer: using decision analysis to improve clinical decision making in urology. Nature Reviews Urology, 2006, 3, 439-448.	1.4	11
507	Temporary Renal Ischemia During Nephron Sparing Surgery is Associated With Short-Term but Not Long-Term Impairment in Renal Function. Journal of Urology, 2006, 176, 1339-1343.	0.4	89
508	Natural History of Positive Urinary Cytology After Radical Cystectomy. Journal of Urology, 2006, 176, 2000-2005.	0.4	25
509	The Association Between Total and Positive Lymph Node Counts, and Disease Progression in Clinically Localized Prostate Cancer. Journal of Urology, 2006, 175, 1320-1325.	0.4	192
510	Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. Journal of Urology, 2006, 176, 100-104.	0.4	70
511	Evaluation of specific and non-specific effects in homeopathy: Feasibility study for a randomised trial. Homeopathy, 2006, 95, 215-222.	1.0	29
512	Homoeopathic Oscillocoquinum for preventing and treating influenza and influenza-like syndromes. , 2006, , CD001957.		16
513	Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. , 2006, , CD002285.		204
514	Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology, 2006, 68, 988-992.	1.0	24
515	Double-Blind, Placebo-Controlled, Randomized Trial of Granulocyte-Colony Stimulating Factor During Postoperative Radiotherapy for Squamous Head and Neck Cancer. Cancer Journal (Sudbury,) Tj ETQq1 1 0.720314 rg52 /Overloc	1.0	24
516	Acupuncture is a feasible treatment for post-thoracotomy pain: results of a prospective pilot trial. BMC Anesthesiology, 2006, 6, 5.	1.8	22
517	Whose data set is it anyway? Sharing raw data from randomized trials. Trials, 2006, 7, 15.	1.6	119
518	Selecting patients for randomized trials: a systematic approach based on risk group. Trials, 2006, 7, 30.	1.6	24
519	Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU International, 2006, 97, 939-945.	2.5	222
520	Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU International, 2006, 98, 59-62.	2.5	47
521	Impact of a Multidisciplinary Continuous Quality Improvement Program on the Positive Surgical Margin Rate after Laparoscopic Radical Prostatectomy. European Urology, 2006, 49, 853-858.	1.9	38
522	Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence?. Cancer, 2006, 106, 576-580.	4.1	59

#	ARTICLE	IF	CITATIONS
523	Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. <i>Cancer</i> , 2006, 106, 2369-2375.	4.1	47
524	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. <i>Cancer</i> , 2006, 107, 506-513.	4.1	360
525	Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. <i>Cancer</i> , 2006, 107, 2167-2172.	4.1	69
526	Standardization of pelvic lymphadenectomy performed at radical cystectomy. <i>Cancer</i> , 2006, 107, 2368-2374.	4.1	215
527	Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. <i>International Journal of Cancer</i> , 2006, 118, 1234-1240.	5.1	48
528	Sialyltransferase STX (ST8Siall): A novel molecular marker of metastatic neuroblastoma. <i>International Journal of Cancer</i> , 2006, 119, 152-156.	5.1	42
529	Acupuncture in Cancer Patient Care. <i>Annals of Traditional Chinese Medicine</i> , 2006, , 265-286.	0.1	0
530	Unconventional Anticancer Agents: A Systematic Review of Clinical Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 136-140.	1.6	31
531	FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor. <i>Journal of Clinical Oncology</i> , 2006, 24, 2885-2890.	1.6	129
532	Decision Curve Analysis: A Novel Method for Evaluating Prediction Models. <i>Medical Decision Making</i> , 2006, 26, 565-574.	2.4	3,292
533	How to Measure Quality of Life in Integrative Oncology Research. , 2006, 04, 100.		4
534	Multiple Assessment in Quality-of-Life Trials: How Many Questionnaires? How Often Should They be Given?. , 2006, 04, 135.		12
535	How to Randomize. <i>Society for Integrative Oncology</i> , 2006, 04, 194.	0.7	113
536	How to design a phase I trial of an anticancer botanical. <i>Society for Integrative Oncology</i> , 2006, 4, 46-51.	0.7	9
537	Analysis of Variance Is Easily Misapplied in the Analysis of Randomized Trials: A Critique and Discussion of Alternative Statistical Approaches. <i>Psychosomatic Medicine</i> , 2005, 67, 652-655.	2.0	86
538	Rituximab therapy of lymphoma is enhanced by orally administered (1 α '3),(1 α '4)-d- β -glucan. <i>Leukemia Research</i> , 2005, 29, 679-683.	0.8	75
539	Positive Surgical Margins and Accessory Pudendal Artery Preservation During Laparoscopic Radical Prostatectomy. <i>European Urology</i> , 2005, 48, 786-792.	1.9	32
540	Acupuncture for dyspnea in advanced cancer: a randomized, placebo-controlled pilot trial [ISRCTN89462491]. <i>BMC Palliative Care</i> , 2005, 4, 5.	1.8	63

#	ARTICLE	IF	CITATIONS
541	Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea and Vomiting. Journal of Clinical Oncology, 2005, 23, 7188-7198.	1.6	168
542	Interpreting data from randomized trials: the Scandinavian prostatectomy study illustrates two common errors. Nature Reviews Urology, 2005, 2, 404-405.	1.4	4
543	High Prevalence of Complementary and Alternative Medicine Use Among Cancer Patients: Implications for Research and Clinical Care. Journal of Clinical Oncology, 2005, 23, 2590-2592.	1.6	106
544	Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. BMC Medical Research Methodology, 2005, 5, 35.	3.1	257
545	ANATOMY OF ACCESSORY PUDENDAL ARTERIES IN LAPAROSCOPIC RADICAL PROSTATECTOMY. Journal of Urology, 2005, 174, 523-526.	0.4	54
546	Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 91-95.	2.5	23
547	Point-Counterpoint: Using Clinical Trials for the Evaluation of Integrative Cancer Therapies. Integrative Cancer Therapies, 2004, 3, 66-81.	2.0	8
548	Letter to the Editor. Integrative Cancer Therapies, 2004, 3, 199-199.	2.0	2
549	Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ: British Medical Journal, 2004, 328, 747.	2.3	149
550	Acupuncture for Postchemotherapy Fatigue: A Phase II Study. Journal of Clinical Oncology, 2004, 22, 1731-1735.	1.6	186
551	Massage therapy for symptom control: outcome study at a major cancer center. Journal of Pain and Symptom Management, 2004, 28, 244-249.	1.2	294
552	Alternative Cancer Cures: "Unproven" or "Disproven"? Ca-A Cancer Journal for Clinicians, 2004, 54, 110-118.	329.8	43
553	Statistical considerations for use of composite health-related quality-of-life scores in randomized trials. Quality of Life Research, 2004, 13, 717-723.	3.1	23
554	Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ: British Medical Journal, 2004, 328, 744.	2.3	263
555	Massage for promoting growth and development of preterm and/or low birth-weight infants. The Cochrane Library, 2004, , CD000390.	2.8	148
556	Placebo in acupuncture trials. Pain, 2004, 109, 195.	4.2	8
557	Incorporating predictions of individual patient risk in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 348-352.	1.6	19
558	Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biology, 2004, 1, 157-163.	1.6	52

#	ARTICLE	IF	CITATIONS
559	Statistical Reanalysis of Four Recent Randomized Trials of Acupuncture for Pain Using Analysis of Covariance. <i>Clinical Journal of Pain</i> , 2004, 20, 319-323.	1.9	46
560	Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation. <i>Cancer</i> , 2003, 98, 2723-2729.	4.1	193
561	Complementary and alternative therapies. <i>Urologic Clinics of North America</i> , 2003, 30, 369-376.	1.8	21
562	How many repeated measures in repeated measures designs? Statistical issues for comparative trials. <i>BMC Medical Research Methodology</i> , 2003, 3, 22.	3.1	88
563	Underpowering in randomized trials reporting a sample size calculation. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 717-720.	5.0	87
564	Soy: An Anticancer Agent In Wide Use Despite Some Troubling Data. <i>Cancer Investigation</i> , 2003, 21, 817-818.	1.3	16
565	Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year. <i>Contemporary Clinical Trials</i> , 2003, 24, 731-735.	1.9	5
566	Use of a single global assessment to reduce missing data in a clinical trial with follow-up at one year. <i>Contemporary Clinical Trials</i> , 2003, 24, 731-735.	1.9	3
567	Placebo Controls in Randomized Trials of Acupuncture. <i>Evaluation and the Health Professions</i> , 2002, 25, 421-435.	1.9	52
568	Immediate effects of dry needling and acupuncture at distant points in chronic neck pain: results of a randomized, double-blind, sham-controlled crossover trial. <i>Pain</i> , 2002, 99, 83-89.	4.2	216
569	Botanical Medicines for the Treatment of Cancer: Rationale, Overview of Current Data, and Methodological Considerations for Phase I and II Trials. <i>Cancer Investigation</i> , 2002, 20, 1069-1079.	1.3	131
570	Orally administered β -glucans enhance anti-tumor effects of monoclonal antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 557-564.	4.2	160
571	Complementary and Alternative Medicine Approaches in Colorectal Cancer. , 2002, , 717-735.		0
572	Regular Article. Complementary Therapies in Medicine, 2001, 9, 127-128.	2.7	1
573	How to reduce the number of patients needed for randomized trials: a basic introduction. <i>Complementary Therapies in Medicine</i> , 2001, 9, 234-236.	2.7	3
574	Unconventional therapies for cancer and cancer-related symptoms. <i>Lancet Oncology</i> , The, 2001, 2, 226-232.	10.7	100
575	Can Homeopathically Prepared Mercury Cause Symptoms in Healthy Volunteers? A Randomized, Double-Blind Placebo-Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2001, 7, 141-148.	2.1	21
576	Alternative medicine use worldwide. <i>Cancer</i> , 2001, 91, 1390-1393.	4.1	68

#	ARTICLE	IF	CITATIONS
577	The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Medical Research Methodology, 2001, 1, 6.	3.1	405
578	Time course of muscle soreness following different types of exercise. BMC Musculoskeletal Disorders, 2001, 2, 5.	1.9	52
579	Message to complementary and alternative medicine: evidence is a better friend than power. BMC Complementary and Alternative Medicine, 2001, 1, 1.	3.7	39
580	Systematic reviews of complementary therapies - an annotated bibliography. Part 1: Acupuncture. BMC Complementary and Alternative Medicine, 2001, 1, 3.	3.7	99
581	Systematic reviews of complementary therapies – an annotated bibliography. Part 3: Homeopathy. BMC Complementary and Alternative Medicine, 2001, 1, 4.	3.7	51
582	Systematic reviews of complementary therapies – an annotated bibliography. Part 2: Herbal medicine. BMC Complementary and Alternative Medicine, 2001, 1, 5.	3.7	55
583	Statistics Notes: Analysing controlled trials with baseline and follow up measurements. BMJ: British Medical Journal, 2001, 323, 1123-1124.	2.3	1,540
584	INCORPORATING DATA FROM DISSERTATIONS IN SYSTEMATIC REVIEWS. International Journal of Technology Assessment in Health Care, 2000, 16, 711-713.	0.5	37
585	Researching complementary medicine. International Journal of Therapy and Rehabilitation, 2000, 7, 26-29.	0.1	0
586	A Last Word from the Original Author. Journal of Alternative and Complementary Medicine, 2000, 6, 302-302.	2.1	0
587	Why use placebos in clinical trials? A narrative review of the methodological literature. Journal of Clinical Epidemiology, 2000, 53, 157-161.	5.0	99
588	The Lure of the Ghetto. Journal of Alternative and Complementary Medicine, 2000, 6, 300-300.	2.1	2
589	Clinical Trials of Homeopathy and Placebo: Analysis of a Scientific Debate. Journal of Alternative and Complementary Medicine, 2000, 6, 49-56.	2.1	29
590	ABC of complementary medicine: Acupuncture. BMJ: British Medical Journal, 1999, 319, 973-976.	2.3	115
591	COMPARISON OF AN ORDINAL AND A CONTINUOUS OUTCOME MEASURE OF MUSCLE SORENESS. International Journal of Technology Assessment in Health Care, 1999, 15, 709-716.	0.5	63
592	ABC of complementary medicine: Herbal medicine. BMJ: British Medical Journal, 1999, 319, 1050-1053.	2.3	161
593	ABC of complementary medicine: Massage therapies. BMJ: British Medical Journal, 1999, 319, 1254-1257.	2.3	105
594	Do Certain Countries Produce Only Positive Results? A Systematic Review of Controlled Trials. Contemporary Clinical Trials, 1998, 19, 159-166.	1.9	613

#	ARTICLE	IF	CITATIONS
595	Homeopathic Arnica 30Å— Is Ineffective for Muscle Soreness After Long-Distance Running: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Journal of Pain</i> , 1998, 14, 227-231.	1.9	72
596	How Should we Research Unconventional Therapies?<i>A Panel Report from the Conference on Complementary and Alternative Medicine Research Methodology, National Institutes of Health</i>. <i>International Journal of Technology Assessment in Health Care</i> , 1997, 13, 111-121.	0.5	94
597	Methodological Issues in Complementary and Alternative Medicine Research: A Personal Reflection on 10 Years of Debate in the United Kingdom. <i>Journal of Alternative and Complementary Medicine</i> , 1996, 2, 515-524.	2.1	24
598	Can Acupuncture have Specific Effects on Health? A Systematic Review of Acupuncture Antiemesis Trials. <i>Journal of the Royal Society of Medicine</i> , 1996, 89, 303-311.	2.0	376
599	De Lange de Klerk et al.'s Study on Homeopathy. <i>Journal of Alternative and Complementary Medicine</i> , 1995, 1, 213-214.	2.1	0
600	Comparison of Objective Measures of Trismus and Salivation With Patient-reported Outcomes Following Treatment for Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 0, , .	2.2	2